EUVIMEDEUVIMED entdecken
Systematische Übersicht

Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data

Reem D Mahmood, Kathryn Graham, Jack Gleeson iD, Richard A Hubner, Juan W Valle, Mairéad G McNamara

Immunotherapy · 2023

DOI: 10.2217/imt-2022-0190 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Immunotherapy, 2023. Verfasst von Reem D Mahmood und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, M20 4BX, UK. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Bayer, BMS and Roche, all outside of the scope of this work, Celgene and Nucana, Servier, Ipsen and NuCana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies. The majority of patients with biliary tract cancer (BTC) present with advanced disease (disease that has spread) that cannot be cured. The current mainstay of treatment for advanced BTC is chemotherapy, which aims to prolong life expectancy to just under 12 months. The need for new, more effective treatments for advanced BTC is crucial. This systematic review summarizes the most recent clinical trials that have tested the use of newer drugs called immunotherapy (PD-1 and PD-L1 monoclonal antibodies) in the treatment of both early-stage and advanced BTC. Fifteen clinical trials have been included, each testing different immunotherapy drugs either alone or in combination with other anti-cancer treatments. Promising results from larger trials, have given hope for longer survival in patients with advanced BTC when treated with immunotherapy plus chemotherapy as their first-line treatment after diagnosis. However, further investigation is required to determine whether certain patients might benefit more than others and if immunotherapy drugs can also be given to patients at an earlier or later stage of their disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsBile Duct NeoplasmsHumansProgrammed Cell Death 1 ReceptorB7-H1 AntigenAntibodies, Monoclonal

Stichwörter der Autor:innen

PD-1 inhibitorPD-L1 inhibitorbiliary tract cancercholangiocarcinomaimmunotherapy

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
  • The Library, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
  • Division of Cancer Sciences, University of Manchester, Manchester, M13 9PL, UK.

ORCID-Profile: Jack Gleeson

Förderung

  • Bayer, BMS and Roche, all outside of the scope of this work
  • Celgene and Nucana
  • Servier, Ipsen and NuCana
  • Bayer and Ipsen and speaker honoraria

Zitieren

APA

Mahmood, R. D., Graham, K., Gleeson, J., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2023). Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data. Immunotherapy. https://doi.org/10.2217/imt-2022-0190

Vancouver

Mahmood RD, Graham K, Gleeson J, Hubner RA, Valle JW, McNamara MG. Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data. Immunotherapy. 2023. doi:10.2217/imt-2022-0190

BibTeX
@article{Mahmood2023,
  author = {Mahmood, Reem D and Graham, Kathryn and Gleeson, Jack and Hubner, Richard A and Valle, Juan W and McNamara, Mairéad G},
  title = {Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2022-0190}
}
Kostenlos starten →